Literature DB >> 19862489

[HPV infections of the oral and genital mucosa. Possibilities for primary prevention].

R Kirnbauer1, C Schellenbacher, S Shafti-Keramat, A Handisurya.   

Abstract

It is well accepted today that almost all cases of carcinoma of the cervix are caused by persistent infections with high-risk human papilloma viruses (HPV), especially through types HPV16 and HPV18 (ca. 70%). These same types are also responsible for some carcinomas of the vulva, anus, penis and oropharynx. This knowledge indicates that it should be possible to prevent these carcinomas if a majority of the causstive HPV infections can be prevented.

Entities:  

Mesh：

Year:  2009        PMID： 19862489     DOI： 10.1007/s00105-009-1803-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  8 in total

1.  Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.

Authors:  A Handisurya; A Rieger; Z Bago-Horvath; C Schellenbacher; A Bankier; A Salat; G Stingl; R Kirnbauer
Journal:  Sex Transm Infect       Date:  2009-08       Impact factor: 3.519

2.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

3.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

4.  Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

Authors:  Alessandra Handisurya; Ratish Gambhira; Christina Schellenbacher; Saeed Shafti-Keramat; Ola Forslund; Michel Favre; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

5.  Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Authors:  Christina Schellenbacher; Richard Roden; Reinhard Kirnbauer
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

Review 6.  Diseases caused by human papillomaviruses (HPV).

Authors:  Alessandra Handisurya; Christina Schellenbacher; Reinhard Kirnbauer
Journal:  J Dtsch Dermatol Ges       Date:  2009-03-06       Impact factor: 5.584

7.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

8.  Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.

Authors:  A Handisurya; A Rieger; A Bankier; A Koller; A Salat; G Stingl; R Kirnbauer
Journal:  Br J Dermatol       Date:  2007-07-19       Impact factor: 9.302
  8 in total
  2 in total

1.  High-risk human papillomavirus (HPV) screening and detection in healthy patient saliva samples: a pilot study.

Authors:  Deidre O Turner; Shelley J Williams-Cocks; Ryan Bullen; Jeremy Catmull; Jesse Falk; Daniel Martin; Jarom Mauer; Annabel E Barber; Robert C Wang; Shawn L Gerstenberger; Karl Kingsley
Journal:  BMC Oral Health       Date:  2011-10-10       Impact factor: 2.757

2.  A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Authors:  Bettina Huber; Christina Schellenbacher; Christoph Jindra; Dieter Fink; Saeed Shafti-Keramat; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.